Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 24;14:17588359211070643. doi: 10.1177/17588359211070643

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2022

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 6. — Low molecular mutational burden was associated with superior response rate and longer survival time. (a) Alterations of six genes, including TRIM24, SPEN, RNF43, PRKAR1A, KRAS, and KDM5 C, were frequently observed in 41 plasma samples at baseline. (b) The significantly different genes in each group. All the significant gene entries have been illustrated in red, whereas other entries are in different degrees of red colors. (c) Molecular mutational burden of six genes was lower in non-PD group compared with PD group. (d) The distribution of patients with PD/non-PD in MMB-high and MMB-low subgroups. (e) PFS was longer in patients with low molecular mutational burden than patients with high molecular mutational burden. (f) OS was longer in low-MMB group than high-MMB group.